Artificial intelligence (AI) can rapidly screen patients for clinical trial enrollment. Their novel AI-assisted patient screening tool significantly improved the speed of determining eligibility and enrollment in a heart failure clinical trial compared to manual screening.
The study randomized 4,476 patients to be either manually screened or screened using generative AI to see if they were eligible for the Co-Operative Program for Implementation of Optimal Therapy in Heart Failure (COPILOT-HF) trial.
A generative AI tool assessed clinical notes and other pieces of information in patients' electronic health records to determine if they met key eligibility criteria for the heart failure study. Criteria included symptoms, chronic diseases, and current and past medications, among others. The AI-assisted screening process was far more efficient, screening 458 eligible patients compared to the 284 patients screened by study staff.
The RECTIFIER tool was slightly more accurate in identifying patient charts that met the heart failure trial's eligibility criteria, compared to manual screening. This new research validates the tool to be highly effective in an active clinical setting.
【MORE】